Radioimmunotherapy: A Review of I-131 Tositumomab and Y-90 Ibritumomab Tiuxetan for the Treatment of NHL

Radioimmunotherapy: A Review of I-131 Tositumomab and Y-90 Ibritumomab Tiuxetan for the Treatment of NHL is organized by eRADIMAGING.

Release Date: 02/05/2022
Expiration Date: 02/08/2028

Course Description:
Non-Hodgkin lymphoma (NHL) is currently the second fastest rising cancer in the United States, with a doubling in incidence over the last 30 years. In addition to more conventional therapy for NHL with chemotherapy, external beam radiation therapy, bone marrow or stem cell transplantation, or a combination of these strategies, radioimmunotherapy (RIT) has been introduced during the past decade and represents a promising therapeutic strategy in patients with B-cell NHL. However, the safe and effective delivery of RIT for NHL requires advanced coordination of care between diverse members of the patient's clinical team, including the nuclear medicine physician, medical oncologist, radiation oncologist, as well as nurses, pharmacists and radiologic technologists. Consequently, radiologic technologists and other professionals responsible for these patients require an understanding of NHL disease, in addition to knowledge of the important operating parameters and safety issues surrounding RIT in these patients. This article will review the signs and symptoms, diagnosis, staging, and treatment options for NHL, with a focus on B-cell NHL. In addition, current options for RIT will be reviewed, with special attention to initial patient evaluation and dosing, follow-up imaging, and important radiation safety concerns for patients, caregivers, family members and institutions delivering care.

Learning Objectives:
After reading this article, the participant should be able to:

• Describe the signs and symptoms associated with non-Hodgkin lymphoma (NHL), as well as the differential diagnosis and staging of NHL disease.
• Identify currently available treatment options of B-cell NHL.
• Explain the differences between radioimmunotherapy treatment options currently available for B-cell NHL.
• Discuss the unique aspects of radioimmunotherapy treatment protocols for NHL.
• Recognize the unique operating challenges, including radiation safety issues, facing institutions that provide radioimmunotherapy treatment services.